This study compared the time course to clinical improvement with clozapine and with conventional antipsychotic medications. A double-blind trial compared clozapine and haloperidol in patients with schizophrenia who were refractory to conventional antipsychotic medication and were hospitalized for 30 to 364 days at 15 Veteran Affairs medical centers during the year before study entry. Patients in the original study were randomly assigned to haloperidol or clozapine and followed for 12 months, at maximum tolerable doses. Patients who completed a full year of treatment with clozapine (n = 122), or with either haloperidol or another conventional antipsychotic medication (n = 123) and who also completed the 9-or 12-month assessment were included. Response to treatment was defined as 20 percent improvement on standard scales of symptoms and quality of life at the latter of the 9-or 12-month interviews. More patients assigned to clozapine achieved 20 percent improvement in symptoms at each followup. Among patients who did not improve at 6 weeks, 3 months, or 6 months, there were no significant differences between clozapine and comparison patients in outcomes at 1 year. Among patients who did improve, maintenance of that improvement also did not differ between the groups at 1 year on symptom measures. Maintenance of improvement in quality of life at 1 year was significantly greater for clozapine patients who had improved at 6 months (p < 0.04). Significant differential symptom response to clozapine occurred exclusively during the first 6 weeks of treatment.
cious than conventional pharmacotherapies in the treatment of refractory schizophrenia-with benefits in both positive and negative symptoms and in quality of life (Kane et al. 1988; Meltzer et al. 1990; Pickar et al. 1992; Breier at al. 1993 Breier at al. , 1994 Lieberman et al. 1994; Carpenter et al. 1995; Rosenheck et al. 1997) . However, clozapine is expensive, and because of the associated risk of potentially fatal agranulocytosis, clozapine treatment requires inconvenient weekly blood monitoring. Treatment with clozapine costs approximately $4,500 per year, plus an additional $1,000 for blood monitoring-11 times the typical annual cost of conventional antipsychotic medications (Meltzer and Cola 1994) . Although some studies have indicated that these higher costs can be offset by reduced hospital use among high-cost patients (Revicki et al. 1991; Meltzer et al. 1993; Reid et al. 1994; Essock et al. 1996; Rosenheck et al. 1997) , there is no evidence that such savings can be realized among refractory outpatients with limited hospital utilization, and potential savings in such patients are likely to be limited (Rosenheck et al. 1993) .
The cost-effectiveness of clozapine treatment in typical clinical practice would be vastly improved if it were possible to rapidly and accurately identify clozapine "responders" and differentiate them from "nonresponders." Such differentiation would allow treatment resources for clozapine to be targeted precisely at those patients who would gain the greatest benefit. While ongoing clinical assessment allows ready identification of patients who have improved with treatment, it is not possible to determine whether the observed improvement is the result of clozapine treatment, and therefore warrants continued clozapine therapy, or would have' occurred with less costly, conventional antipsychotic treatment. Although clozapine is specifically indicated for refractory (i.e., nonresponsive) schizophrenia patients, virtually every conReprint requests should be sent to Dr. R. Rosenheck, VA Connecticut Healthcare System, 950 Campbell Ave., West Haven, CT 06516-2770; e-mail: Robert.Rosenheck@Yale.edu. trolled study of clozapine has reported improvement among some refractory patients treated with conventional antipsychotic medications and nonimprovement among some patients treated with clozapine. It is thus virtually impossible in clinical practice to identify individual clozapine responders who would not have responded to less costly medications. Further information is needed to guide longitudinal clinical decisionmaking.
One approach to this problem is to identify a targeted time course for response to clozapine. In such an approach patients who have not shown significant improvement after a specified time would be regarded as nonresponders, and their clozapine treatment would be discontinued. The challenge is to identify the appropriate timeframe for evaluating responsiveness. If the timeframe is too short, some patients who would benefit from clozapine would be excluded from long-term treatment. If the timeframe is too long, some nonresponsive patients will receive sustained clozapine treatment without benefiting from it. In addition to costing less, specifying a timeframe would reduce the risk of agranulocytosis and seizures associated with clozapine treatment.
Most of these studies addressing the time course have demonstrated early response to clozapine, as soon as 1 week after initiating treatment (Pickar et al. 1992; Stern et al. 1994) , while others have reported new responses occurring up to 1 year after treatment initiation (Wilson 1996) . Lieberman et al. (1994) suggested that the optimal trial was from 3 to 6 months, although Meltzer and colleagues (1990; Meltzer 1992 ) indicated a need for trials lasting from 6 to 12 months. Our understanding of the course of response to clozapine is further complicated by an unreplicated study showing that in 25 percent of clozapine responders, the initial improvement on the drug is not sustained by 1 year (Zito et al. 1993) . A recent review of published studies concluded that the evidence for late response to clozapine is limited (Carpenter et al. 1995) .
A major limitation of previous studies of time to clozapine response is that they have not systematically compared the time course of response to clozapine with the time course of response to treatment with standard antipsychotic medications in a sample of comparable patients. Although there is substantial evidence that (1) refractory schizophrenia patients are more likely to show significant improvement on clozapine than on conventional antipsychotic medications, and (2) that response to clozapine often occurs up to 6 months after treatment initiation, there is no evidence that a differential response to clozapine eventually appears among patients who have shown no initial response to treatment.
In this paper we use data from a 12-month study of clozapine and haloperidol in a sample of patients with refractory schizophrenia that compared treatment response at 6 weeks, 3 months, 6 months, and 1 year. We define treatment response as a 20 percent improvement on either Positive and Negative Syndrome Scale (PANSS; Kay et al. 1987) or the Heinrichs-Carpenter Quality of Life Scale (Heinrichs et al. 1984) . We further examine 1-year medication responses among two subgroups of these patients: (1) patients who had not responded to treatment at various time points (i.e., time-specific nonresponders) and (2) patients who had responded at the various time points (i.e., time-specific responders). Through these analyses we attempt to elucidate differential clozapine versus haloperidol response rates as well as maintenance rates among subgroups of treatment responders and nonresponders. We hope these data will provide useful information to guide longitudinal clinical decisionmaking.
Methods
Data for this study were obtained from a prospective, double-blind study, in which schizophrenia patients refractory to antipsychotic medication were recruited over 2 years at 15 Veterans Affairs (VA) medical centers. Patients were randomly assigned to clozapine or haloperidol and treated for 12 months. The protocol was approved by a human rights committee at the Hines VA Cooperative Studies Program Coordinating Center and by human rights committees at each participating medical center. All patients gave written informed consent.
Entry Criteria
Hospital use criteria. The study was targeted at a subgroup of currently hospitalized treatment-refractory schizophrenia patients with a history of high inpatient service use, defined as at least 30 days' hospitalization for schizophrenia during the previous year, and no more than 364 days.
Clinical criteria. Clinical eligibility criteria modeled on those of Kane et al. (1988) included (1) (Spitzer and Endicott 1990) ; (2) refractoriness defined as persisting psychotic symptoms despite two documented adequate treatment trials; (3) severe symptoms indicated by scores on the Brief Psychiatric Rating Scale (Overall and Gorham 1962) and the Clinical Global Impression Scale (Guy 1976); and (4) serious social dysfunction for the previous 2 years.
Exclusion criteria. Patients were excluded if they were unable to give informed consent or had a previous trial of clozapine; had a current myeloproliferative disorder; or were pregnant.
After providing written informed consent to participate in the study and completing baseline assessments, patients were randomly assigned, within centers, to a treatment group.
Pharmacotherapy. Random assignment was made to double-blind treatment with clozapine (100-900 mg/day) or haloperidol (5-30 mg/day). Dose adjustments were made as clinically indicated, using 12 fixed dosage levels. Haloperidol-treated patients also received benztropine mesylate (2-10 mg/day) for extrapyramidal side effects while clozapine patients received a matching benztropine placebo. Haloperidol patients participated in weekly blood counts as required for clozapine treatment.
Psychosodal Treatment. To assess the potential effectiveness of clozapine in typical clinical practice, a predefined program of adjunctive psychotherapeutic and rehabilitative treatments was offered through a structured treatment planning module based on a comprehensive menu of locally available services. This system ensured that all patients were encouraged to use psychosocial services that could be of therapeutic value to them.
Assessment of Outcomes and Reliability of Ratings.
Symptom outcomes were assessed with the structured clinical.interview of the PANSS (Kay et al. 1987 ) (range = 30-210, with higher scores reflecting more severe symptoms). Social functioning and quality of life were evaluated with the Heinrichs-Carpenter Quality of Life Scale, a clinician-rated scale of social functioning and severe behavioral deficits (Heinrichs et al. 1984) (range = 0-126 with higher scores reflecting higher functioning). Interviews were conducted at 6 weeks and at 3, 6, 9, and 12 months after random assignment. Outcome data for the present study were based on the latter of the 9-and 12-month interviews, and patients for whom these interviews were missing were excluded from the analyses. Improvement of 20 percent on these scales was regarded as a clinically significant response.
All interviewers were formally trained and received annual reassessment of interrater reliability using ratings from videotaped demonstration interviews. A statistical method was developed to assess the reliability of multiple assessments in a single patient or taped interview (Cicchetti et al. 1997) . Reliability across interviewers (n = 39), as assessed by this method, was excellent for both the PANSS (96% agreement; range = 94-96% across subscales) and the Heinrichs-Carpenter Quality of Life Scale (95% agreement; range = 90-98% across subscales).
Crossovers. During the 12 months of followup, some patients stopped taking study medication because of lack of efficacy or adverse effects and switched to other treatments. Thus some clozapine patients received standard antipsychotic medications (including haloperidol), and some haloperidol patients received clozapine. Altogether, 83 (40%) of 205 patients assigned to clozapine discontinued it by the 48th week of the trial and crossed to a standard antipsychotic medication (including haloperidol). Although 157 (72%) of the 218 haloperidol patients were unblinded, only 49 (22%) received clozapine treatment for 4 or more weeks during the trial; they were excluded from the analyses.
The inclusion of these "crossover" patients in our analyses would have distorted our evaluation of the timing of medication response, so all the analyses presented here were conducted with crossover cases excluded. Patients in the clozapine group were treated with clozapine for at least 48 weeks, while patients in the control group received conventional antipsychotic medications for the entire period.
Analyses were conducted to determine how the crossover patients differed from those who did not cross over. Examination of 25 sociodemographic and clinical status measures showed that crossover patients were not significantly different from those who did not cross over on any baseline clinical or demographic measure, except that they had better quality of life on the HeinrichsCarpenter Quality of Life Scale (p = 0.01). However, within the subgroup of patients who did not cross over, there were no significant differences between treatment groups at baseline. Thus, although the original study was based on random assignment, the subsamples of each treatment group examined in this study were not randomly assigned. Although no significant differences were noted between treatment groups, the analyses presented here must be regarded as coming from a nonequivalent control group design since group assignment was not completely random. It should also be noted again that only 61 of the haloperidol patients were blind throughout the trial.
Methods of Analysis.
Chi-square tests were used to determine the significance of differences between groups in the proportion who had achieved 20 percent improvement at each time point. Further analyses, limited to 1-year outcomes among patients who had improved or had not improved at each assessment point, also used the chisquare test of statistical significance.
Results
Sample Characteristics. Table 1 presents sociodemographic and clinical characteristics of the sample. There were no significant differences between the two groups on any measure. During the first half of the trial (weeks 1- 26), average doses were 431 mg/day for clozapine and 22.9 mg/day for haloperidol. During the second half of the trial (weeks 27-53), average doses were 628 mg/day for clozapine and 28.2 mg/day for haloperidol. Improvement Over Time: Entire Sample. Figure 1 shows that rates of improvement among patients assigned to clozapine increased steadily, but the incremental increase from one time point to the next was far greater during the first 6 weeks (29%) than in subsequent time periods (8%, 3%, and 1% respectively). Improvement in the group treated with haloperidol was also substantial but occurred more slowly.
A significantly higher percentage of patients assigned to clozapine had achieved a 20 percent improvement in symptoms at 6 weeks (X 2 = 11.1, df = \,p < 0.001) and at 6 months (X 2 = 9.87, df=l,p-0.002). Trends suggested higher percentages of improvement among clozapine patients at 3 months (X 2 = 2.83, df= \,p = 0.08) and at 1 year (X 2 = 3.18, df= l,/? = 0.08). On the Quality of Life Scale (figure 2), improvement in the clozapine group was also steady with 29 percent and 43 percent showing improvement at 6 weeks and 3 months, and smaller increases thereafter. The comparison group showed the same likelihood of improvement in quality of life at 6 weeks, but smaller increases thereafter. Statistical analysis showed trends suggesting significant differences between the clozapine and haloperidol groups at 6 months (X 2 = 2.51, df= 1, p = 0.11) and 1 year (X 2 = 4.22, df=\,p = 0.04). Attaining Improvement Among Time-Specific Nonresponders. Table 2 compares 1-year outcome responses among specific subgroups who did not show a 20 percent response to treatment at each time point during the trial. The first comparison, using the PANSS, shows that among patients whose symptoms had not responded to treatment by 6 weeks, 27.1 percent of clozapine patients and virtually the same percentage of haloperidol patients (25.7%) responded by 1 year. Results were quite similar for each group of time-specific nonresponders, with an average response rate of 25 percent of clozapine patients and 21 percent of control patients.
Results for change in quality of life are also generally similar across nonresponding groups, although among 6-week nonresponders, a marginally significant difference is observed at 1 year with 42 percent of clozapine patients responding by 1 year versus 29 percent of those assigned to haloperidol (X 2 = 2.97, df= l,p = 0.09). There were no significant differences between treatment groups in 1-year quality of life outcomes among 3-month and 6-month nonresponders.
Maintaining Improvement Among Responders. Table  3 presents data on 1-year symptom and quality of life status among patients who had previously shown 20 percent improvement, thus reflecting the maintenance of gains through sustained treatment.
There were no significant differences between treatment groups on maintenance of symptom improvement (PANSS), regardless of when their improvement was observed. Across all groups, an average of 69 percent of clozapine patients and 68 percent of comparison patients maintained their 20 percent improvement in symptoms.
On the quality of life measure, in contrast, an average of 83 percent of clozapine patients who had improved at each time point maintained their improvement at 1 year, compared with an average of 69 percent of comparison patients. Groups were differentiated by nonsignificant trends (p < 0.10) at 3 months and by a significant difference at 6 months (p < 0.05).
Medication Dose Levels.
Comparison of average daily clozapine doses during the first 6 months of the study showed no significant difference between those who showed 20 percent improvement on the PANSS at 6 months (mean average dose = 413 mg/day, SD =161) and those who did not (mean average dose = 439 mg/day, SD = 156) (t = 0.91, df= 98.3, p = 0.36). There was also no difference between those who showed 20 percent improvement on the Quality of Life Scale at 6 months (mean average dose = 427 mg/day, SD = 159) and those who did not (mean average dose = 431 mg/day, SD = 157) (t = 1.17; df= 47.7, p = 0.24). Significant dosage differences were also absent between haloperidol improvers and nonimprovers and between groups sorted by response type during the last 6 months of the study.
Discussion
This study compared time course of response to treatment among comparable samples of refractory schizophrenia patients who were treated for a full year with either clozapine or conventional antipsychotic medications. Patients selected for these analyses were those who had not crossed over to the other treatment condition during a randomized clinical trial, and who had completed a formal clinical assessment at either 9 or 12 months. Although the study was derived from a randomized clinical trial, since crossover cases were excluded, group assignment was not completely random and only 61 control cases remained blinded throughout the trial. The largest proportion of patients who obtained substantial clinical improvement in both the clozapine and conventional antipsychotic groups did so during the first 6 weeks of treatment. While differences between treatment groups in the proportion of responders was greatest on the measure of symptoms at 6 weeks, group differences in quality of life were greatest at 1 year. Thus while clinical improvement in both symptoms and quality of life occurred most frequently in both treatment groups, during the first 6 weeks of the trial, differences between the groups, which invariably favored the clozapine group, emerged at different times-early in the trial for symptom measures, but late in the trial in the case of quality of life improvements. These findings were not explained by differences in medication dosage.
Rates of overall improvement are based on achieving significant levels of improvement when it has not previously been achieved, and maintaining improvement once it has been achieved. A particular strength of this study is that it tracked the time course of both of these processes for both the clozapine group and the comparison group. Examination of symptom outcomes showed significant differences in improvement during the first 6 weeks of the trial, but no significant differences in either achieving or retaining improvement after the first 6 weeks of treatment. Thus both absolute and relative rates of symptom improvement are concentrated during the first 6 weeks of treatment.
In contrast, differences in achieving quality of life outcomes at 1 year were marginally significantly different among patients who had not achieved improvement by 3 months, although not among subsequent groups of nonresponders. Patients treated with clozapine, however, were more likely to maintain quality of life improvements achieved during the first 6 months of the trial through to the 1-year interview. This study thus replicated the findings of Zito et al. (1993) . The probability of retaining improvement is what distinguishes clozapine's long-term impact on quality of life. As with symptom improvement, long-term clozapine responders achieve their improvement early in the trial, suggesting that decisions about continuing treatment with clozapine can be made on the basis of the early response. The differential benefit of clozapine largely results from the greater likelihood of retaining that improvement among those who responded.
Before we draw conclusions for clinical practice from these data, several potential methodological limitations must be noted. First, the early responders may have been those with the best prognoses at baseline. The similar rates of incremental improvement between groups at later time points may be due to the fact that clozapine patients who had not responded by 6 weeks were sicker at baseline than haloperidol nonresponders and therefore had poorer prognoses. To evaluate this possibility we conducted an additional analysis in which we compared 6-week nonresponders on all baseline measures listed in table 1. These analyses showed no significant differences between the 6-week symptom and quality of life nonresponder groups on any of the sociodemographic or clinical variables.
Second, the lack of subsequent differential response to clozapine and conventional antipsychotic medications among 6-week treatment nonresponders does not unambiguously demonstrate that clozapine patients would have responded just as positively if they had been treated with conventional antipsychotic medications. A study design that re-randomized treatment nonresponders in both groups at 6 weeks to either haloperidol or clozapine would better address this question, but this would require a much larger sample size. In the absence of such a study, the current data suggest that patients who have not responded to clozapine by 6 weeks are not likely to have a better response to clozapine as compared with conventional antipsychotic medications over the remainder of the year of treatment. Patients who have responded to clozapine, in contrast, were more likely to maintain their gains, at least in the domain of social functioning, with continued clozapine treatment.
Third, this study considered only outcomes in symptoms and quality of life. Clozapine has a dramatically superior extrapyramidal symptom profile compared with standard antipsychotic medications at all time points Rosenheck et al. 1997) . For some patients, this may be reason enough to use clozapine as a medication of choice (Kane et al. 1988; Lieberman et al. 1994) , although it also adds a small risk of agranulocytosis. In addition, by reducing hospital use clozapine has significant potential cost savings (see below). Furthermore, since the PANSS measures factors other than psychotic symptoms, it is possible that clozapine response in some individuals was diluted by changes in these other areas.
Finally, our inclusion of patients who were refractory to conventional antipsychotic medication (many of whom probably had failed previous trials of haloperidol) but not patients with a previous trial of clozapine may have biased the results in favor of clozapine to some degree. Given the limited use of clozapine at the time this study was conducted, this bias was unavoidable.
If the findings reported here are supported by subsequent studies, clozapine pharmacotherapy could be provided through standardized 6-week trials accompanied by systematic outcome monitoring with standardized instruments. Responders at 6 weeks would be continued on clozapine, while nonresponders could be switched to a standard neuroleptic. Table 4 presents cost data using methods from the original study (1,900) 1 Average cost associated with clozapine treatment less cost of haloperidol treatment. 2 Estimate based on assumption that nonresponders (71% of the sample) would shift to haloperidol treatment after 6 weeks of treatment with clozapine. 3 Outpatient services include professional services and laboratory visits including those required by the study protocol. 4 Costs for the haloperidol group have been adjusted for services exclusively required for the study protocol to 73 percent of their actual value.
that illustrate the economic consequences of such a strategy. In the intention-to-treat analysis in the original study, health care costs associated with clozapine were nonsignificantly lower than haloperidol costs by $2,441 because of reductions in hospital utilization. In this study sample, average 1-year health care costs were $3,435 higher because crossover cases, who took clozapine for only part of the year, were excluded. Outpatient costs (including medication and laboratory costs) associated with clozapine pharmacotherapy were $8,495 greater than costs associated with haloperidol treatment, and inpatient savings of $5,060 were not sufficient to offset this greater cost. However, when costs are reestimated assuming that (1) there is no loss of drug efficacy if 6-week nonresponders are changed to standard antipsychotic medication, and (2) 71 percent of patients do not respond to clozapine within 6 weeks (as was found in this study), then we would expect outpatient clozapine therapy to cost only $3,160 more. Total health care costs would then be $1,900 lower with clozapine than with haloperidol. By lowering the cost of treatment, this strategy would support clozapine trials with increased numbers of patients and would allow more efficient targeting of the drug.
Conclusion
Data on the time course of treatment response to clozapine presented here are substantially more informative than those of previous studies because data on a parallel comparison group treated with conventional antipsychotic medications are included. Because of the methodological limitations of the trial design these data are not strong enough to obviate the need for clozapine trials in ordinary practice of greater duration than 6 weeks. They do suggest that incremental benefits in symptoms and quality of life, beyond those achievable with conventional medications, are most likely to be realized among patients who respond to clozapine during the first 6 weeks of treatment. If differential response to clozapine can be determined from a 6-week trial, cost savings could be substantial, and greater numbers of patients could have access to the drug.
